Published ahead of print on August 15, 2002, doi:10.1164/rccm.200203-268OC
Am. J. Respir. Crit. Care Med., Volume 166, Number 10, November 2002, 1403-1408
A more recent version of this article appeared on November 15, 2002
Submitted on April 1, 2002
Accepted on August 6, 2002
Simvastatin Attenuates Smooth Muscle Neointimal Proliferation and Pulmonary Hypertension in Rats
Toshihiko Nishimura1, John L Faul1, Gerald J Berry2, Laszlo Vaszar1, Daoming Qiu1, Ronald G Pearl3, and Peter N Kao1*
1 Pulmonary and Critical Care Medicine, Stanford University Medical Center, Stanford, CA, USA,
2 Pathology, Stanford University Medical Center, Stanford, CA, USA,
3 Anesthesiology, Stanford University Medical Center, Stanford, CA, USA
* To whom correspondence should be addressed. E-mail: peterkao{at}stanford.edu.
Hypertensive pulmonary vascular disease (HPVD) involves abnormal proliferation of endothelial and smooth muscle cells, leading to occlusion of pulmonary arterioles, pulmonary hypertension, right ventricular failure and death. Compounds with antiproliferative effects on endothelial and smooth muscle cells, such as HMG CoA-reductase inhibitors, may prevent the development of experimental HPVD. Pneumonectomized rats injected with monocrotaline at 7 days develop severe HPVD with neointimal formation. Rats were randomized to receive either vehicle or treatment with the HMG CoA-reductase inhibitor, simvastatin (2 mg/kg/day). By Day 35, rats that received vehicle had higher mean pulmonary arterial pressures (mPpa = 53 ± 2 mm Hg) and right ventricular hypertrophy (right ventricle/(left ventricle plus septum)(RV/LV+S = 0.78 ± 0.09) than rats in Groups PMS5-35 (mPpa = 27 ± 3 mm Hg, RV/LV+S = 0.34 ± 0.08; p 0.001). Pulmonary vascular remodeling with neointimal formation consisting of smooth muscle cells was more severe in vehicle-treated rats (1.98 ± 0.02), than in Group PMS5-35 (0.59 ± 0.46; p < 0.001). Additionally, lung endothelial nitric oxide synthase (eNOS) expression was decreased in vehicle-treated animals but was restored toward normal by simvastatin. Simvastatin attenuates monocrotaline-induced vascular remodeling with neointimal formation, pulmonary arterial hypertension, and right ventricular hypertrophy in rats.
Key words: Hypertension, pulmonary ; endothelium ; cholesterol ; nitric oxide synthase
This article has been cited by other articles:

|
 |

|
 |
 
N. Homma, T. Nagaoka, V. Karoor, M. Imamura, L. Taraseviciene-Stewart, L. A. Walker, K. A. Fagan, I. F. McMurtry, and M. Oka
Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone
Am J Physiol Lung Cell Mol Physiol,
July 1, 2008;
295(1):
L71 - L78.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Takahashi, H. Nakamura, M. Seki, Y. Shiraishi, M. Yamamoto, M. Furuuchi, T. Nakajima, S. Tsujimura, T. Shirahata, M. Nakamura, et al.
Reversal of elastase-induced pulmonary emphysema and promotion of alveolar epithelial cell proliferation by simvastatin in mice
Am J Physiol Lung Cell Mol Physiol,
May 1, 2008;
294(5):
L882 - L890.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Carlin, A. J. Peacock, and D. J. Welsh
Fluvastatin Inhibits Hypoxic Proliferation and p38 MAPK Activity in Pulmonary Artery Fibroblasts
Am. J. Respir. Cell Mol. Biol.,
October 1, 2007;
37(4):
447 - 456.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. McMurtry, S. Bonnet, E. D. Michelakis, S. Bonnet, A. Haromy, and S. L. Archer
Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study
Am J Physiol Lung Cell Mol Physiol,
October 1, 2007;
293(4):
L933 - L940.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Laudi, S. Trump, V. Schmitz, J. West, I. F. McMurtry, H. Mutlak, U. Christians, J. Weimann, U. Kaisers, and W. Steudel
Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin
Am J Physiol Lung Cell Mol Physiol,
September 1, 2007;
293(3):
L630 - L638.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. R. Bauer, T. M. Moore, and I. F. McMurtry
Rodent models of PAH: are we there yet?
Am J Physiol Lung Cell Mol Physiol,
September 1, 2007;
293(3):
L580 - L582.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Li, Y. Liu, P. Dutt, B. L. Fanburg, and D. Toksoz
Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin
Am J Physiol Lung Cell Mol Physiol,
August 1, 2007;
293(2):
L463 - L471.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Mangat, S. Agarwal, and C. Rosendorff
Do Statins Lower Blood Pressure?
Journal of Cardiovascular Pharmacology and Therapeutics,
June 1, 2007;
12(2):
112 - 123.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. E. Girgis, S. Mozammel, H. C. Champion, D. Li, X. Peng, L. Shimoda, R. M. Tuder, R. A. Johns, and P. M. Hassoun
Regression of chronic hypoxic pulmonary hypertension by simvastatin
Am J Physiol Lung Cell Mol Physiol,
May 1, 2007;
292(5):
L1105 - L1110.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Taraseviciene-Stewart, R. Scerbavicius, K.-H. Choe, C. Cool, K. Wood, R. M. Tuder, N. Burns, M. Kasper, and N. F. Voelkel
Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension
Am J Physiol Lung Cell Mol Physiol,
October 1, 2006;
291(4):
L668 - L676.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. I. Said
Mediators and modulators of pulmonary arterial hypertension
Am J Physiol Lung Cell Mol Physiol,
October 1, 2006;
291(4):
L547 - L558.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Murata, K. Kinoshita, M. Hori, M. Kuwahara, H. Tsubone, H. Karaki, and H. Ozaki
Statin Protects Endothelial Nitric Oxide Synthase Activity in Hypoxia-Induced Pulmonary Hypertension
Arterioscler. Thromb. Vasc. Biol.,
November 1, 2005;
25(11):
2335 - 2342.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-H. Lee, D.-S. Lee, E.-K. Kim, K.-H. Choe, Y.-M. Oh, T.-S. Shim, S.-E. Kim, Y.-S. Lee, and S.-D. Lee
Simvastatin Inhibits Cigarette Smoking-induced Emphysema and Pulmonary Hypertension in Rat Lungs
Am. J. Respir. Crit. Care Med.,
October 15, 2005;
172(8):
987 - 993.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Kawut, E. M. Horn, K. K. Berekashvili, A. C. Widlitz, E. B. Rosenzweig, and R. J. Barst
von Willebrand Factor Independently Predicts Long-term Survival in Patients With Pulmonary Arterial Hypertension
Chest,
October 1, 2005;
128(4):
2355 - 2362.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. van Albada, R. G. Schoemaker, M. S. Kemna, A. H. Cromme-Dijkhuis, R. van Veghel, and R. M. F. Berger
The role of increased pulmonary blood flow in pulmonary arterial hypertension
Eur. Respir. J.,
September 1, 2005;
26(3):
487 - 493.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. T. Schermuly, H. Yilmaz, H. A. Ghofrani, K. Woyda, S. Pullamsetti, A. Schulz, T. Gessler, R. Dumitrascu, N. Weissmann, F. Grimminger, et al.
Inhaled Iloprost Reverses Vascular Remodeling in Chronic Experimental Pulmonary Hypertension
Am. J. Respir. Crit. Care Med.,
August 1, 2005;
172(3):
358 - 363.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. N. Kao
Simvastatin Treatment of Pulmonary Hypertension: An Observational Case Series
Chest,
April 1, 2005;
127(4):
1446 - 1452.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Newman, B. L. Fanburg, S. L. Archer, D. B. Badesch, R. J. Barst, J. G.N. Garcia, P. N. Kao, J. A. Knowles, J. E. Loyd, M. D. McGoon, et al.
Pulmonary Arterial Hypertension: Future Directions: Report of a National Heart, Lung and Blood Institute/Office of Rare Diseases Workshop
Circulation,
June 22, 2004;
109(24):
2947 - 2952.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Rubin and N. Galie
Pulmonary arterial hypertension: a look to the future
J. Am. Coll. Cardiol.,
June 16, 2004;
43(12_Suppl_S):
89S - 90S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. T. Vaszar, T. Nishimura, J. D. Storey, G. Zhao, D. Qiu, J. L. Faul, R. G. Pearl, and P. N. Kao
Longitudinal transcriptional analysis of developing neointimal vascular occlusion and pulmonary hypertension in rats
Physiol Genomics,
April 13, 2004;
17(2):
150 - 156.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Abe, H. Shimokawa, K. Morikawa, T. Uwatoku, K. Oi, Y. Matsumoto, T. Hattori, Y. Nakashima, K. Kaibuchi, K. Sueishi, et al.
Long-Term Treatment With a Rho-Kinase Inhibitor Improves Monocrotaline-Induced Fatal Pulmonary Hypertension in Rats
Circ. Res.,
February 20, 2004;
94(3):
385 - 393.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Hironaka, M. Hongo, A. Sakai, E. Mawatari, F. Terasawa, N. Okumura, A. Yamazaki, Y. Ushiyama, Y. Yazaki, and O. Kinoshita
Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats
Cardiovasc Res,
December 1, 2003;
60(3):
692 - 699.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Nishimura, L. T. Vaszar, J. L. Faul, G. Zhao, G. J. Berry, L. Shi, D. Qiu, G. Benson, R. G. Pearl, and P. N. Kao
Simvastatin Rescues Rats From Fatal Pulmonary Hypertension by Inducing Apoptosis of Neointimal Smooth Muscle Cells
Circulation,
September 30, 2003;
108(13):
1640 - 1645.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. E. Girgis, D. Li, X. Zhan, J. G. N. Garcia, R. M. Tuder, P. M. Hassoun, and R. A. Johns
Attenuation of chronic hypoxic pulmonary hypertension by simvastatin
Am J Physiol Heart Circ Physiol,
August 7, 2003;
285(3):
H938 - H945.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Wedgwood and S. M. Black
Induction of apoptosis in fetal pulmonary arterial smooth muscle cells by a combined superoxide dismutase/catalase mimetic
Am J Physiol Lung Cell Mol Physiol,
August 1, 2003;
285(2):
L305 - L312.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. N. Kao and J. L. Faul
Emerging therapies for pulmonary hypertension: Striving for efficacy and safety
J. Am. Coll. Cardiol.,
June 18, 2003;
41(12):
2126 - 2129.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Tobin
Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2002
Am. J. Respir. Crit. Care Med.,
February 1, 2003;
167(3):
356 - 370.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Rubin
Therapy of Pulmonary Hypertension: The Evolution from Vasodilators to Antiproliferative Agents
Am. J. Respir. Crit. Care Med.,
November 15, 2002;
166(10):
1308 - 1309.
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 American Thoracic Society
|
|
|